How to Get Belsomra in Michigan

What Is Belsomra and Why Is It Prescribed?

Belsomra (suvorexant) is an oral dual orexin receptor antagonist (DORA) that the FDA approved in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance. Unlike benzodiazepines or Z-drugs, suvorexant works by blocking orexin-A and orexin-B neuropeptides, the wake-promoting signals in the lateral hypothalamus. This mechanism produces sleep without the GABA-mediated sedation that drives many of the dependence and next-day impairment risks seen with older hypnotics.

The key registration trial by Herring et al. (2012, N=3,032) demonstrated that suvorexant at 40 mg and 20 mg significantly improved subjective total sleep time (sTST) at month 1 and month 3 compared to placebo [1]. A separate 12-month safety study confirmed that suvorexant maintained efficacy without evidence of rebound insomnia upon discontinuation [2]. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults, citing moderate-quality evidence from these controlled trials [3].

Michigan has approximately 1.2 million adults who report short sleep duration according to CDC Behavioral Risk Factor Surveillance System data, making access to effective insomnia pharmacotherapy a real clinical need across the state [4].

Michigan Telehealth Prescribing Rules for Belsomra

Michigan law permits telehealth prescribing of Schedule IV controlled substances, which includes suvorexant. A provider does not need to conduct an in-person visit first. This applies statewide.

Under Michigan Public Act 4 of 2020, a prescriber may establish a provider-patient relationship via a real-time, two-way audiovisual telehealth encounter [5]. The Michigan Board of Pharmacy and the DEA both recognize telehealth-issued prescriptions for Schedule IV drugs, provided the prescriber holds an active Michigan medical license and a current DEA registration. The AASM 2020 position statement supports telehealth for insomnia management, noting that "telehealth visits for insomnia diagnosis and treatment, including pharmacotherapy, are clinically appropriate and can improve access to care in underserved areas" [3].

For practical purposes, this means a Michigan resident can complete a video consultation with a licensed provider, receive an electronic Belsomra prescription sent directly to a Michigan pharmacy, and pick up or have the medication shipped within days. No separate in-person visit is legally required. Rural areas in the Upper Peninsula, where sleep medicine specialists are sparse, benefit most from this pathway.

One restriction applies. Audio-only telephone visits may not satisfy Michigan's prescribing requirements for new controlled substance prescriptions. The encounter must include a video component unless the patient has an established relationship and a documented prior in-person or video visit.

Who Can Prescribe Belsomra in Michigan?

Several provider types hold prescriptive authority. The list is broader than many patients expect.

Michigan grants full Schedule IV prescriptive authority to physicians (MD, DO), nurse practitioners (NP), and physician assistants (PA), provided each holds a current DEA registration with Schedule IV privileges. Under the Michigan Public Health Code, NPs who have completed a minimum 2,000-hour practice agreement (or who practice under the 2024 expanded full-practice-authority provisions) may independently prescribe suvorexant without physician co-signature [5]. PAs prescribe under a practice agreement with a supervising physician, but the prescription itself is valid at any Michigan pharmacy.

Dentists and optometrists do not have prescriptive authority for insomnia medications under Michigan law. Psychologists cannot prescribe in Michigan at all.

When choosing a provider, confirm three things: an active license on the Michigan LARA verification portal, a DEA registration that includes Schedule IV, and willingness to prescribe DORAs (some providers default to trazodone or generic zolpidem and may require a conversation about why suvorexant is appropriate for your specific presentation).

Belsomra Dosing and What to Expect Before Prescribing

Providers typically start at 10 mg taken within 30 minutes of bedtime with at least 7 hours of planned sleep remaining. The FDA label permits a range from 5 mg to 20 mg.

Before writing a Belsomra prescription, most Michigan providers will review a sleep history and rule out obstructive sleep apnea (OSA), which affects an estimated 12% of Michigan adults based on NHANES prevalence extrapolations [6]. Standard screening includes the STOP-Bang questionnaire and Epworth Sleepiness Scale. Formal polysomnography is not required before prescribing suvorexant, but a provider may order it if OSA risk is high.

Routine labs are not mandated by the FDA label. No hepatic or renal panel is required for suvorexant initiation in otherwise healthy adults. Patients with moderate hepatic impairment should not exceed 10 mg. Those with severe hepatic impairment should avoid suvorexant entirely, per the FDA prescribing information [2].

The Herring et al. Lancet Neurology trial (2014, N=254 in the 3-month efficacy cohort) showed that suvorexant 20 mg improved wake after sleep onset (WASO) by 22.4 minutes compared to placebo at month 1 (P<0.01) [1]. Patients often notice improvement in sleep continuity within the first 1 to 3 nights, though the full clinical benefit may take up to 1 week to stabilize.

Drug interactions matter. Suvorexant is metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) are contraindicated with suvorexant because they can more than double plasma levels [2]. Moderate inhibitors like diltiazem, erythromycin, and fluconazole require a dose reduction to 5 mg. Providers in Michigan should review the patient's medication list carefully before prescribing, especially in older adults with polypharmacy.

Michigan Medicaid and Insurance Coverage for Belsomra

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers Belsomra with prior authorization (PA). This is not optional. Without PA approval, the pharmacy claim will reject.

The Michigan Department of Health and Human Services (MDHHS) Preferred Drug List places Belsomra in a non-preferred tier for insomnia, which triggers the PA requirement [7]. The standard PA criteria require documentation that the patient has tried and failed (or has a contraindication to) at least one first-line generic agent, typically zolpidem, eszopiclone, or low-dose doxepin. Some Medicaid managed care plans in Michigan (Molina, Priority Health, Meridian, HAP Midwest) apply their own PA forms, but the clinical criteria are similar.

A complete PA submission for Belsomra in Michigan typically requires:

• The patient's insomnia diagnosis (ICD-10: G47.00 or F51.01)
• Documentation of prior medication trials and their outcomes
• The prescriber's rationale for suvorexant over available generics
• The requested dose and expected duration of therapy

Turnaround time for Michigan Medicaid PA decisions is 24 hours for standard requests and 4 hours for urgent requests, per federal Medicaid regulations [7]. If denied, the prescriber can file a formal appeal. The denial letter will include instructions.

For commercial insurance in Michigan, coverage varies by plan. Blue Cross Blue Shield of Michigan and Priority Health both list Belsomra on Tier 3 (non-preferred brand) with PA in most formularies. The average commercial copay with PA approval ranges from $30 to $75 per month, depending on the plan. Without insurance, the cash price for a 30-day supply of brand Belsomra runs approximately $380 to $450 at Michigan retail pharmacies, though Merck's savings card can reduce the out-of-pocket cost to as low as $10 per month for eligible commercially insured patients.

503A Compounding Pharmacies in Michigan

Michigan licenses 503A compounding pharmacies that can prepare suvorexant formulations. This is a real option for patients who need custom dosing.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding medications pursuant to individual patient prescriptions [8]. In Michigan, these pharmacies are regulated by the Michigan Board of Pharmacy and must comply with both state and USP <795> standards for non-sterile compounding.

Why would a patient use a 503A pharmacy for suvorexant? Three common reasons: the commercially available tablet strengths (5, 10, 15 to 20 mg) do not match the dose the provider wants to prescribe; the patient cannot swallow tablets and needs a liquid suspension; or the patient wants to avoid specific inactive ingredients in the brand product. A compounding pharmacy can prepare suvorexant in custom doses (for example, 7.5 mg or 12.5 mg) or in alternative dosage forms.

Michigan-licensed 503A pharmacies can ship compounded suvorexant within the state. Interstate shipping of compounded controlled substances is more restricted and generally requires the pharmacy to hold licenses in both the originating and receiving states. For Michigan residents filling at a Michigan pharmacy, in-state shipping is straightforward.

To use a 503A pharmacy, the patient's provider sends a patient-specific prescription directly to the compounding pharmacy. The pharmacy then sources pharmaceutical-grade suvorexant powder, compounds the formulation, and dispenses it. Turnaround is typically 3 to 5 business days from prescription receipt.

Transferring a Belsomra Prescription to Michigan

Patients relocating to Michigan or visiting for an extended period can transfer an existing Belsomra prescription from another state, with conditions.

Michigan follows the standard DEA transfer protocol for Schedule IV prescriptions. A prescription can be transferred between pharmacies one time only [5]. The receiving Michigan pharmacy contacts the originating out-of-state pharmacy, verifies the prescription details, and records the transfer. Both pharmacies must document the transfer in their records. Remaining refills transfer with the prescription.

For patients who cannot transfer (for example, the prescription has already been transferred once, or the originating pharmacy has closed), the simplest path is a new telehealth visit with a Michigan-licensed provider. This visit can often be completed the same day, and a new prescription can be sent to any Michigan pharmacy electronically.

Michigan does not accept paper prescriptions written by out-of-state providers for Schedule IV controlled substances filled at Michigan pharmacies unless the prescriber also holds a Michigan license. Electronic prescriptions from out-of-state providers with valid DEA registrations are accepted at Michigan pharmacies, but practices vary. Confirming with the receiving pharmacy before the transfer saves time.

Timeline: From Consultation to Medication in Hand

Most patients move from initial consultation to medication pickup in 3 to 7 business days. Some complete the process faster.

Here is a realistic timeline for a new patient in Michigan:

Day 1: Schedule and complete a telehealth visit with a Michigan-licensed prescriber. If no PA is required (commercial insurance with Belsomra on formulary, or cash pay), the provider sends the e-prescription immediately.

Day 1 to 2: The pharmacy receives and processes the prescription. If the medication is in stock, it can be ready for pickup or shipping the same day.

Day 1 to 3 (if PA is required): The provider's office submits the PA to the insurer. Michigan Medicaid returns a decision within 24 hours. Commercial insurers typically respond within 48 to 72 hours.

Day 3 to 5: PA approved, pharmacy dispenses. For mail-order or 503A compounding, add 2 to 3 days for shipping.

Day 5 to 7: Medication arrives for mail-order or compounded prescriptions.

Cash-pay patients who use a local retail pharmacy with Belsomra in stock can sometimes have the medication in hand on the same day as their telehealth visit. The bottleneck is almost always prior authorization, not prescribing or dispensing.

Safety, Side Effects, and Michigan-Specific Considerations

The most common side effect of suvorexant is next-morning drowsiness, reported in 7% of patients taking 20 mg vs. 3% on placebo in the Phase III program [1]. The FDA label carries a warning about complex sleep behaviors (sleepwalking, sleep-driving), though the incidence in clinical trials was less than 1% [2].

Suvorexant is classified as Schedule IV by the DEA, reflecting a low but real abuse potential. The 2017 AASM guideline states that "the abuse liability of suvorexant appears to be lower than that of zolpidem or benzodiazepine receptor agonists, based on available human abuse potential studies" [3]. Michigan's Prescription Drug Monitoring Program (PDMP), known as MAPS (Michigan Automated Prescription System), requires prescribers to check the patient's PDMP report before issuing a new controlled substance prescription. This check takes under 2 minutes and is integrated into most Michigan EHR systems [5].

Patients taking suvorexant should avoid alcohol, which potentiates CNS depression. The FDA label also warns against driving or operating heavy machinery until the patient knows how the drug affects them, recommending a minimum of 7 hours between dosing and any activity requiring full alertness [2].

For Michigan patients who work early-morning shifts (common in the state's manufacturing and automotive sectors), the 10 mg starting dose with strict 7-hour sleep window counseling is especially important. Providers should explicitly discuss next-morning impairment risk with patients whose alarm goes off before 5:30 AM.

Suvorexant vs. Other Insomnia Medications Available in Michigan

Suvorexant is not the only option. Understanding the alternatives helps patients and providers make an informed choice.

Lemborexant (Dayvigo): Another DORA, FDA-approved in 2019. The SUNRISE-2 trial (N=949) demonstrated that lemborexant 5 mg and 10 mg both improved sTST compared to placebo at 6 months [9]. Lemborexant is available at Michigan pharmacies and has a similar PA profile to suvorexant on most formularies.

Zolpidem (Ambien): The most commonly prescribed insomnia medication in Michigan. Generic zolpidem costs $5 to $15 per month and requires no PA on most plans. The tradeoff: higher rates of complex sleep behaviors, rebound insomnia, and abuse liability compared to DORAs [3].

Low-dose doxepin (Silenor): FDA-approved for sleep maintenance insomnia at 3 mg and 6 mg. Not a controlled substance. Useful for patients who cannot take Schedule IV drugs due to substance use history or prescriber preference.

Cognitive Behavioral Therapy for Insomnia (CBT-I): The AASM and the American College of Physicians both recommend CBT-I as first-line therapy for chronic insomnia [10]. Michigan has multiple CBT-I providers available via telehealth. Suvorexant can be used alongside CBT-I for the initial weeks while behavioral changes take effect.

The choice between suvorexant and alternatives depends on the patient's insomnia pattern (onset vs. maintenance), comorbidities, medication interactions, insurance formulary, and prior treatment history. A 2023 network meta-analysis in the Annals of Internal Medicine (N=36,533 across 154 RCTs) found that DORAs had the most favorable balance of efficacy and tolerability among all pharmacologic insomnia treatments for adults [11].